Anti-Infective Drugs Market to Reach US$ 187.5 Billion by 2035 as Drug-Resistance Concerns and Next-Generation Therapies Reshape Infection Treatment

Anti-infective drugs are medicines used to prevent and treat infections caused by pathogens. The category includes antibacterials, antivirals, antifungals, and antiparasitic drugs, each designed to target specific infectious organisms or mechanisms.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=41204

These therapies remain fundamental to modern healthcare because they reduce infection severity, complications, mortality, and treatment duration. Antibiotics continue to account for a major share of anti-infective use, treating conditions ranging from respiratory infections to severe sepsis. Antivirals are also increasingly important for diseases such as HIV, hepatitis, and influenza.

Anti-infective drugs have enabled major advances in healthcare. Procedures such as organ transplantation, cancer treatment, and complex surgery can be performed more safely because effective therapies help prevent and manage serious infections.

Market Overview

The global anti-infective drugs market was valued at US$ 132.6 billion in 2024 and is expected to grow at a 3.2% CAGR between 2025 and 2035, surpassing US$ 187.5 billion by 2035.

Market expansion is being supported by rising infectious disease burdens, increased healthcare spending, public health programs, and pharmaceutical innovation. Governments and international health organizations are also increasing efforts to improve access to essential anti-infective medicines, particularly across low- and middle-income countries.

Technology is transforming drug discovery. Artificial intelligence and machine learning are increasingly being explored to identify promising drug candidates, accelerate research, improve clinical development, and potentially reduce discovery timelines.

Demand is also shifting toward patient-friendly treatment options, including oral therapies and long-acting injectable formulations. Microbiome-based therapies and immunotherapies represent emerging areas that could further expand the anti-infective treatment landscape.

Key Drivers of Market Growth

Rising prevalence of infectious diseases is a primary market driver. Urbanization, international travel, inadequate sanitation in some regions, climate-related changes, and the emergence or re-emergence of pathogens can increase infection transmission and healthcare demand.

The continuing burden of pneumonia, sepsis, tuberculosis, HIV, hepatitis, influenza, and other infectious diseases sustains demand for effective therapies.

Antimicrobial resistance is another critical growth factor. Resistance against existing antibiotics and other anti-infective medicines is increasing the need for next-generation treatments. Pharmaceutical companies are therefore investing in novel antimicrobials, combination therapies, and alternative mechanisms of action.

An aging global population is also supporting demand. Older adults can face greater susceptibility to infections because of age-related changes in immune function and the presence of multiple underlying health conditions. Hospitals, nursing facilities, and long-term care centers therefore represent important areas of anti-infective utilization.

Key Players and Industry Leaders

The competitive landscape includes major pharmaceutical companies with broad portfolios, established manufacturing capabilities, and significant R&D investments.

Leading companies include Pfizer Inc., Gland Pharma Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Jiangsu Simcere Pharmaceutical Co., Ltd., Novartis AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Astellas Pharma Inc., Alkem, AstraZeneca, Johnson & Johnson Services, Inc., Sanofi, and Abbott.

Key Trends for the Future

Several trends are expected to shape the market through 2035.

First, AI-enabled drug discovery is gaining momentum as companies seek faster identification and validation of promising candidates.

Second, long-acting injectable and convenient oral formulations are attracting attention because they can improve treatment adherence and simplify patient management.

Third, precision and targeted therapies are becoming increasingly relevant as researchers seek treatments that address specific pathogens while reducing unwanted effects.

Another emerging trend is the development of microbiome-based therapies and immunotherapies, which aim to support or enhance the body's natural defenses against infection.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/antiinfective-drugs-market.html

New Opportunities and Challenges

The growing need for treatments against resistant pathogens creates significant opportunities for pharmaceutical and biotechnology companies. Novel antibiotics, next-generation antivirals, antifungals, combination therapies, and targeted delivery technologies can address important unmet medical needs.

Emerging markets also offer substantial opportunities as healthcare infrastructure improves and governments expand access to essential medicines.

At the same time, drug resistance, high R&D costs, complex clinical trials, regulatory requirements, and commercial challenges associated with antibiotics can constrain market development. Maintaining innovation while ensuring affordability and responsible medicine use will remain essential.

Market Trends & Innovations

Antiviral drugs currently represent a leading segment of the global anti-infective drugs market, supported by the continuing need to manage viral diseases and advances in antiviral development.

Innovation is increasingly focused on therapies with improved efficacy, safety, dosing convenience, and resistance profiles. Digital health systems are also helping pharmaceutical companies and healthcare providers strengthen patient monitoring and support clinical trials.

Recent industry developments demonstrate continued innovation. In July 2025, Merck announced U.S. FDA acceptance of its New Drug Application for doravirine/islatravine, an investigational two-drug oral regimen for virologically suppressed adults with HIV-1. In April 2024, Pfizer received European Commission authorization for EMBLAVEO (aztreonam-avibactam) for several serious bacterial infections in adults with limited treatment options.

Future Outlook

North America held a leading position in the anti-infective drugs market in 2024, supported by advanced healthcare infrastructure, access to innovative medicines, pharmaceutical R&D capabilities, and initiatives addressing healthcare-associated infections and antimicrobial resistance.

Looking ahead, market growth will increasingly depend on the ability of pharmaceutical companies to deliver innovative therapies while improving accessibility and affordability. AI-driven discovery, next-generation antimicrobials, long-acting formulations, microbiome therapies, and immunotherapeutic approaches are expected to create new avenues for growth.

With the global market projected to reach US$ 187.5 billion by 2035, the anti-infective drugs industry is positioned for steady expansion. Companies capable of combining scientific innovation with effective commercialization and global access strategies are likely to gain a competitive advantage.

Market Segmentation

The anti-infective drugs market can be segmented by:

Drug Class: Antibacterials, antifungals, antivirals, and other anti-infectives

Drug Availability: Over-the-counter and prescription

Route of Administration: Oral, parenteral, topical, rectal/vaginal, nasal, and others

Formulation: Capsules, tablets, creams/gels, liquids/solutions, powders, and others

Indication: Pneumonia, sepsis, tuberculosis, candidiasis, hepatitis, HIV, COVID-19, MRSA, and others

Distribution Channel: Hospital pharmacies, retail pharmacies, and online pharmacies

Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=41204<ype=S

Important FAQs with Answers

What was the size of the anti-infective drugs market in 2024?

The global market was valued at approximately US$ 132.6 billion in 2024.

What is the projected market size by 2035?

The market is projected to exceed US$ 187.5 billion by 2035.

What is the expected CAGR during 2025–2035?

The market is expected to expand at a 3.2% CAGR.

Which drug class is leading the market?

Antiviral drugs are a leading segment, supported by continued demand for therapies targeting major viral infections.

What is the major challenge facing the industry?

Antimicrobial resistance is one of the most significant challenges, creating demand for innovative treatments while reducing the effectiveness of some existing therapies.

More Trending Reports by Transparency Market Research –

Brain Health Supplements Market: https://www.transparencymarketresearch.com/brain-health-supplements-market.html

Human Papillomavirus Vaccine Market: https://www.transparencymarketresearch.com/human-papillomavirus-vaccine-market.html

Allergy Immunotherapy Market: https://www.transparencymarketresearch.com/allergy-immunotherapy-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com